Is baricitinib useful for Dabai Lung?

Great White Pneumonia (COVID-19) is a respiratory infectious disease caused by a new type of coronavirus. To date, baricitinib has not been approved as a standalone treatment for white lung disease.

However, baricitinib has been used in some studies as an adjunctive treatment for white lung disease. Baricitinib is a Janus kinase (JAK) inhibitor that regulates immune responses by inhibiting inflammatory responses and cytokine release. This makes baricitinib considered potentially helpful in the treatment of great white lung.

One study found that in patients with large white lung, baricitinib combined with an antiviral drug such as remdesivir reduced length of stay and the need for mechanical ventilation compared with standard care alone. However, the exact efficacy and safety of baricitinib in the treatment of white lung are still being evaluated in further studies.

So if you or someone you know has great white lung, it is best to seek advice from a professional doctor or medical provider. Only a physician can evaluate a patient's specific situation and decide whether baricitinib is appropriate for use as adjuvant treatment for white lung disease. Remember, treatment options for great white lung should be developed by your doctor based on the latest clinical guidelines and research.

Baricitinib has been launched in China and is included in medical insurance. Patients can purchase it domestically. Due to different medical insurance reimbursement policies in different regions, the reimbursement ratio is also different. The price is about 1200~1600 yuan. For specific prices, please consult the local pharmacy or the medical insurance bureau. Baricitinib has both original and generic drugs abroad. The original drug is mainly Eli Lilly’s original drug, and its price is higher than in China. Generic drugs are mainly Bangladeshi generic drugs, and the price is around 450 yuan. The ingredients of original drugs and generic drugs are basically the same.